GlaxoSmithKline plc’s “Market Perform” Rating Reaffirmed at Sanford C. Bernstein (GSK)
GlaxoSmithKline plc (LON:GSK)‘s stock had its “market perform” rating restated by analysts at Sanford C. Bernstein in a research report issued to clients and investors on Wednesday. They currently have a GBX 1,650 ($28.01) price objective on the stock. Sanford C. Bernstein’s target price would indicate a potential upside of 4.00% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Tuesday. They now have a GBX 1,700 ($28.86) price target on the stock. Separately, analysts at Societe Generale raised their price target on shares of GlaxoSmithKline plc from GBX 2,075 ($35.22) to GBX 2,100 ($35.65) in a research note on Thursday, June 12th. They now have a “buy” rating on the stock. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Tuesday, June 3rd. They now have a GBX 1,660 ($28.18) price target on the stock. Four investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the stock. GlaxoSmithKline plc presently has an average rating of “Hold” and a consensus target price of GBX 1,713.24 ($29.08).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1588.00 on Wednesday. GlaxoSmithKline plc has a one year low of GBX 1200.668 and a one year high of GBX 1762.0001. The stock’s 50-day moving average is GBX 1617. and its 200-day moving average is GBX 1615.. The company’s market cap is £76.446 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.